Paula Kjollerstrom

Dr. Paula Kjollerstrom

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 July 2025 in Blood Cancer Journal
Verified
Journal Article
Open access
PDF file
LKLili Kotmayer
Lili Kotmayer
EKEmilia J. Kozyra
Emilia J. Kozyra
Guolian KangGuolian Kang
Guolian Kang
BSBrigitte Strahm
Brigitte Strahm
AYAyami Yoshimi
Ayami Yoshimi
MWMarcin W. Wlodarski
Marcin W. Wlodarski
GATA2 deficiency is an autosomal dominant transcriptopathy disorder with high risk for myelodysplastic syndrome (MDS). To elucidate genotype-phenotype associations and identify new genetic risk factors for MDS, we analyzed 218 individuals with germline heterozygous GATA2 variants. We observed striking age-dependent incidence patterns in GATA2-related MDS (GATA2-MDS), with MDS being absent in infants, rare before age 6 years, and steeply increasing in older children. Among 108 distinct GATA2 variants (67 novel), null mutations conferred a 1.7-fold increased risk for MDS, had earlier MDS onset compared to other variants (12.2 vs. 14.6 years, p = 0.009) and were associated with lymphedema and deafness. In contrast, intron 4 variants exhibited reduced penetrance and lower risk for MDS development. Analysis of the somatic landscape revealed unique patterns of clonal hematopoiesis. SETBP1 mutations occurred exclusively in patients with monosomy 7 and their frequency decreased with age. Conversely, the frequency of STAG2 mutations and trisomy 8 increased with age and appeared protective against early development of advanced MDS. Overall, the majority (73.9%) of mutation-positive cases harbored monosomy 7, suggesting it serves as a major driver in malignant progression. Our findings provide evidence for age-appropriate surveillance, and a foundation for genotype-driven risk stratification in GATA2 deficiency.

2 May 2019 in Pediatric Blood & Cancer
Verified
Journal Article
Closed access
PDF file
BLBruno Loureiro
Bruno Loureiro
SBSara Batalha
Sara Batalha
ERElsa Rocha
Elsa Rocha
RMRaquel Maia
Raquel Maia
PKPaula Kjollerstrom
Paula Kjollerstrom

Verified
Journal Article
Open access
PDF file
Diogo Martins RodriguesDiogo Martins Rodrigues
Diogo Martins Rodrigues
AMAna Marcão
Ana Marcão
LLLurdes Lopes
Lurdes Lopes
AVAna Ventura
Ana Ventura
TFTeresa Ferreira Faria
Teresa Ferreira Faria
LVLaura Vilarinho
Laura Vilarinho
The Portuguese Newborn Screening Program currently includes 28 pathologies: congenital hypothyroidism, cystic fibrosis, 24 inborn errors of metabolism, sickle cell disease and spinal muscular atrophy. This pilot study for sickle cell disease newborn screening, including 188,217 samples, was performed between May 2021 and December 2023, with phase I, including 24,130 newborns, in the Lisbon and Setubal districts and phase II, including 164,087 newborns, in the whole country. DBS samples were analyzed through capillary electrophoresis. In phase I, a high birth incidence of sickle cell disease was found (1:928 NBs), resulting from the identification of 24 HbSS and 2 HbSC patients. This birth incidence decreased but remained significant when the pilot study for sickle cell disease newborn screening was expanded to a national level, with the identification of 67 sickle cell disease patients (59 HbSS and 8 HbSC), revealing a birth incidence of 1:2449 NBs. These data suggest that this condition is becoming increasingly relevant in Portugal, thus reflecting a general European trend, where sickle cell disease is already recognized as a public health problem. Therefore, it highlights the importance of its integration into the Portuguese National Newborn Screening Program panel in January 2024, thus allowing the early identification and clinical follow-up of these patients.

20 August 2026 in Research and Practice in Thrombosis and Haemostasis
Verified
Journal Article
Open access
Gili KenetGili Kenet
Gili Kenet
BRBerrueco Rubén
Berrueco Rubén
KFKarin Fijnvandraat
Karin Fijnvandraat
PKPaula Kjollerstrom
Paula Kjollerstrom
MLMatteo Luciani
Matteo Luciani
MCManuel Carcao
Manuel Carcao

16 January 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
Diogo Martins RodriguesDiogo Martins Rodrigues
Diogo Martins Rodrigues
AMAna Marcão
Ana Marcão
LLLurdes Lopes
Lurdes Lopes
AVAna Ventura
Ana Ventura
TFTeresa Ferreira Faria
Teresa Ferreira Faria
LVLaura Vilarinho
Laura Vilarinho
The Portuguese Newborn Screening Program currently includes 28 pathologies: congenital hypothyroidism, cystic fibrosis, 24 inborn errors of metabolism, sickle cell disease and spinal muscular atrophy. This pilot study for sickle cell disease newborn screening, including 188,217 samples, was performed between May 2021 and December 2023 – Phase I including 24,130 newborns in Lisbon and Setubal districts; Phase II including 164,087 newborns in whole country. DBS samples were analyzed through capillary electrophoresis. In phase I, a high birth prevalence of sickle cell disease was found (1:928 NB), resulting from the identification of 24 HbSS and 2 HbSC patients. This birth prevalence decreased but remained significant when the pilot study for sickle cell disease newborn screening was expanded to a national level, with the identification of 67 sickle cell disease patients (59 HbSS and 8 HbSC), revealing a birth prevalence of 1:2,449 NB. These data suggest that this condition is becoming increasingly relevant in Portugal, thus reflecting a general European trend, where sickle cell disease is already recognized as a public health problem. Therefore, it highlights the importance of its integration into the Portuguese National Newborn Screening Program panel in January 2024, thus allowing the early identification and clinical follow-up of these patients.

19 October 2022 in Journal of Pediatric Hematology/Oncology
Verified
Journal Article
Closed access
MDMariana Duarte
Mariana Duarte
MBMadalena Almeida Borges
Madalena Almeida Borges
PKPaula Kjollerstrom
Paula Kjollerstrom
RMRaquel Maia
Raquel Maia